Henrїk Jespersen

New #JITC article: "Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial)" jitc.bmj.com/content/14/3/e… @OlofssonBagge @SahlgrenskaAcad

Having a hard time believing this. Can’t wait to see this scrutinized, and replicated.

Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive! Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival. However, there was always the question of systematic bias selecting for healthier patients in morning infusions, when frailer patients may not be able to come to receive morning infusions. This could potentially explain retrospective results, that may seem too good to be true… Now we have a randomized clinical trial coming from Dr Zhang and colleagues showing a hazard ratio for Overall Survival of … 0.45 ! Lung cancer, chemo-immunotherapy first-line Looking forward to dig further into the data, and these findings for sure have to be replicated (we are working on that 🇨🇭 @SAKK_ch) But impressive efforts and results, congrats to the authors.👏 @Alfdoc2

@pashtoonkasi @OncoAlert Amazing. Why the brackets on cures?

#ASCO25 More followup on IPI/NIVO 🆚 NIVO immunotherapy showing robust durable efficacy translating to “cures” for the patients with colorectal cancer whose tumors are mismatch repair deficient (🔴dMMR/MSI-High). @OncoAlert ❓Hard to tease out ALL-Lines 🆚1st line. Thoughts 💭

I am grateful to Crown Prince Regent Haakon and Crown Princess Mette-Marit of Norway for the audience. We discussed strengthening cultural ties between our countries and further support for the Grain from Ukraine humanitarian initiative. All of us in Ukraine deeply appreciate Norway’s defense and humanitarian support, as well as its efforts in developing a European plan for achieving a just peace and reliable security guarantees. 🇺🇦🇳🇴

Very proud to present the latest review we wrote about extracellular vesicles in uveal melanoma published in Cancer Letters! @Ornella_Urzi @OlofssonBagge #EV #UM sciencedirect.com/science/articl…

A modified classification of progressive disease based on PD patterns in patients treated with immune checkpoint inhibitors showed an association with postprogression survival (PPOS) across various solid tumor. ja.ma/4gGdagZ

What is the best 1st line immunotherapy regimen for pts with adv/meta melanoma? To me, this remains an unsolved Q because IPI-NIVO and RELA-NIVO are more toxic than NIVO, and post-progression access to IPI-containing regiment in both trials was limited ➡️ mini 🧵1/2 1⃣ RELATIVITY-047 presented 3-y OS results Here is some context for post-progression therapy👇

@nrfn "Lust and learning,' Katherine once said. 'That's really all there is, isn't it?' -J Williams

November @sitcancer #JITC Reading List by Social Media Editor @Praveen_IO selection #4: 15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by @UTSWMedCenter @umiamimedicine bit.ly/3CGwont

📢New @myESMO guidelines in press - Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @ProfGLongMIA @beckilee @TeresaSAmaral @OmidHamidMD @angelesclinic @matguc @DoniaMarco doi.org/10.1016/j.anno…

An important piece of work by @SocSurgOnc for clinicians managing #melanoma patients. Bottom line: gene-expression profiling (GEP) shows much promise but not quite ready for melanoma primetime. Honoured to be involved with this prestigious committee 🇺🇲🇬🇧

BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Physics to John J. Hopfield and Geoffrey E. Hinton “for foundational discoveries and inventions that enable machine learning with artificial neural networks.”

@DrJonasANilsson 😂 Featuring the #1 hit “Super Stormtrooper”

The Solo Album

Happy to share the final version of our @eLife manuscript on tumor-reactive lymphocytes (TRLs) in uveal melanoma elifesciences.org/articles/91705 By using single cell seq and a live biobank of TILs & patient-derived mice (xenografts) we tease out the molecular characteristics of TRLs! ->

@BeckiLee 100% agree

Concerned about the standard arm in this randomised study - if fit enough for TIL should be fit enough for ipi nivo or nivo rela not pembro as the comparator. Something to consider carefully.

@AnnalenaLauren Låter som Svinesund

Körde nyss in i Tyskland från Polen. Genom de omtalade nya gränskontrollerna som de förskräckliga tyskarna infört. De bestod i att alla vinkades förbi utom vi som vinkades in, en blick i baksätet och vi vinkades vidare utan att ens hinna stanna bilen.

@DrJNaidoo @RenoHemonc @myESMO Cool! Any hopes of this being translatable to ir-pneumonitis?

#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 @myESMO

@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24

Can we all just agree now that these patients are cured? Time to stop the cautious talk about “long term benefit” and start giving patients with stage IV melanoma real hope. Final survival analysis of CM067 (nivo/ipi+nivo/ipi) in advanced melanoma. nejm.org/doi/full/10.10…